Human <i>RPE65</i> Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 YearArtur V. Cideciyan, Samuel G. Jacobson, Alexander Sumaroka et al.|Human Gene Therapy|2009Cited by 312
Safety of Recombinant Adeno-Associated Virus Type 2–RPE65 Vector Delivered by Ocular Subretinal InjectionSamuel G. Jacobson, William W. Hauswirth, Gregory M. Acland et al.|Molecular Therapy|2006Cited by 223
Vision 1 Year after Gene Therapy for Leber's Congenital AmaurosisArtur V. Cideciyan, Samuel G. Jacobson, William W. Hauswirth et al.|New England Journal of Medicine|2009Cited by 199
881. Safety, Efficacy and Biodistribution of Recombinant AAV2-RPE65 Vector Delivered by Ocular Subretinal InjectionSamuel G. Jacobson, William W. Hauswirth, Gregory M. Acland et al.|Molecular Therapy|2006Cited by 0